These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 19767155)
1. Risk management and post-marketing surveillance of CNS drugs. Henningfield JE; Schuster CR Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S56-64. PubMed ID: 19767155 [TBL] [Abstract][Full Text] [Related]
2. Introduction to College on Problems of Drug Dependence special conference on risk management and post-marketing surveillance of CNS drugs. Schuster CR; Barthwell AG; Henningfield JE Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S4-8. PubMed ID: 19783381 [No Abstract] [Full Text] [Related]
3. Risk management and post-marketing surveillance of CNS drugs: an introduction. Balster RL; Johanson CE; Walsh SL Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S1-3. PubMed ID: 19744805 [No Abstract] [Full Text] [Related]
4. Risk management of drug products and the U.S. Food and Drug Administration: evolution and context. Leiderman DB Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S9-S13. PubMed ID: 19307069 [TBL] [Abstract][Full Text] [Related]
5. Monitoring risk: post marketing surveillance and signal detection. Dart RC Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S26-32. PubMed ID: 19748743 [TBL] [Abstract][Full Text] [Related]
6. Risk evaluation and mitigation strategies for drugs with abuse liability: public interest, special interest, conflicts of interest, and the industry perspective. Wright C; Schnoll S; Bernstein D Ann N Y Acad Sci; 2008 Oct; 1141():284-303. PubMed ID: 18991964 [TBL] [Abstract][Full Text] [Related]
7. Abuse deterrent formulations and the Controlled Substances Act (CSA). Sapienza FL Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S23-30. PubMed ID: 16529882 [TBL] [Abstract][Full Text] [Related]
8. Case histories in pharmaceutical risk management. McCormick CG; Henningfield JE; Haddox JD; Varughese S; Lindholm A; Rosen S; Wissel J; Waxman D; Carter LP; Seeger V; Johnson RE Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S42-55. PubMed ID: 19767156 [TBL] [Abstract][Full Text] [Related]
9. National addictions vigilance intervention and prevention program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Butler SF; Budman SH; Licari A; Cassidy TA; Lioy K; Dickinson J; Brownstein JS; Benneyan JC; Green TC; Katz N Pharmacoepidemiol Drug Saf; 2008 Dec; 17(12):1142-54. PubMed ID: 18932173 [TBL] [Abstract][Full Text] [Related]
10. Risk management and post-marketing surveillance for the abuse of medications acting on the central nervous system: expert panel report. Johanson CE; Balster RL; Henningfield JE; Schuster CR; Anthony JC; Barthwell AG; Coleman JJ; Dart RC; Gorodetzky CW; O'Keeffe C; Sellers EM; Vocci F; Walsh SL Drug Alcohol Depend; 2009 Dec; 105 Suppl 1(Suppl 1):S65-71. PubMed ID: 19783383 [TBL] [Abstract][Full Text] [Related]
11. Signal detection in post-marketing surveillance for controlled substances. Dasgupta N; Schnoll SH Drug Alcohol Depend; 2009 Dec; 105 Suppl 1():S33-41. PubMed ID: 19616902 [TBL] [Abstract][Full Text] [Related]
12. Risk identification, risk assessment, and risk management of abusable drug formulations. Wright C; Kramer ED; Zalman MA; Smith MY; Haddox JD Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S68-76. PubMed ID: 16581201 [TBL] [Abstract][Full Text] [Related]
13. The role of scientific evidence of risks and benefits in determining risk management policies for medications. Andrews E; Dombeck M Pharmacoepidemiol Drug Saf; 2004 Sep; 13(9):599-608. PubMed ID: 15362082 [TBL] [Abstract][Full Text] [Related]
14. Principles of assessment of abuse liability: US legal framework and regulatory environment. Rocha BA Behav Pharmacol; 2013 Sep; 24(5-6):403-9. PubMed ID: 23820327 [TBL] [Abstract][Full Text] [Related]
15. Understanding risk evaluation and mitigation strategies in organ transplantation. Gabardi S Pharmacotherapy; 2011 Jul; 31(7):714-22. PubMed ID: 21923459 [TBL] [Abstract][Full Text] [Related]
16. Formulation considerations for the development of medications with abuse potential. Mansbach RS; Moore RA Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S15-22. PubMed ID: 16472940 [TBL] [Abstract][Full Text] [Related]
17. The Diversion of Ultram, Ultracet, and generic tramadol HCL. Inciardi JA; Cicero TJ; Munoz A; Adams EH; Geller A; Senay EC; Woody GE J Addict Dis; 2006; 25(2):53-8. PubMed ID: 16785220 [TBL] [Abstract][Full Text] [Related]
18. Research design strategies to evaluate the impact of formulations on abuse liability. McColl S; Sellers EM Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S52-62. PubMed ID: 16554125 [TBL] [Abstract][Full Text] [Related]
19. Regulatory challenges for new formulations of controlled substances in today's environment. McCormick CG Drug Alcohol Depend; 2006 Jun; 83 Suppl 1():S63-7. PubMed ID: 16567060 [TBL] [Abstract][Full Text] [Related]
20. Issues and critiques of the forthcoming risk evaluation and mitigation strategy (REMS) for opioids in pain management. Peppin JF; Coleman JJ; Kirsh KL Issues Law Med; 2011; 27(2):91-119. PubMed ID: 22372206 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]